💨 Abstract

Akebia Therapeutics Inc. (AKBA) reported a first-quarter net income of $6.1 million, reversing a loss from the same period last year. The company earned $0.03 per share and generated $57.3 million in revenue, both surpassing analyst expectations. AKBA's stock closed at $2.46, nearly double its price from a year ago. This positive performance highlights the company's growth in developing kidney disease treatments.

Courtesy: wtop.com